Have you heard of antibody-drug conjugates (ADCs)? These innovative therapies are becoming a promising option for more targeted cancer treatment, and our researchers are at the forefront of advancing their potential. Curious to learn more? 🔗 Hear from our leading experts: bit.ly/42ZvUTd

#News for #investors & #media: Today at #EASLCongress, we’re presenting results from a phase III trial in chronic hepatitis B, a disease affecting approximately 240 million people globally. Learn more: gsk.to/3S77yoc

#News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow. Learn more: gsk.to/49hUlis

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded population by the Japanese Ministry of Health, Labour and Welfare (MHLW). Learn more: gsk.to/4eSI47M

At our recent virtual event with Washington Post Live Hesham Abdullah, Global Head of Oncology R&D at GSK and Peter Lee, President of Microsoft Science, shared how cutting-edge technology is fuelling the mission to improve outcomes for people living with cancer – and to do so more quickly.

#News for #investors and #media: At #ATS2026, we’ll be presenting data across 33 abstracts to highlight our research as we work to redefine respiratory care. gsk.to/4nmDlx9

News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q1 performance and start to 2026 ⤵️ Find out more: gsk.to/4ePgo3m#Investors#Media $GSK #earnings

#News for #investors and #media: Today we are announcing that our potential treatment for chronic hepatitis B has been accepted for regulatory review by US FDA. Learn more: gsk.to/3Qz28Sq

#News for #investors and #media: Today we announced that our investigational liver therapy received US FDA Breakthrough Therapy and EMA Priority Medicine (PRIME) regulatory designations for metabolic dysfunction-associated steatohepatitis (MASH). Find out more: gsk.to/3Qp3P4V

Symptoms of CRSwNP, like nasal obstruction, facial pain and sleep disturbances, can greatly impact a person’s quality of life. Today, on #WorldCRSwNPDay, we’re reinforcing our commitment to improving patient outcomes. See how: gsk.to/4twp830

#News for #Investors and #Media China’s National Medical Products Administration (NMPA) has approved our therapy to treat an incurable and challenging blood cancer. For more information, visit: gsk.to/3QPIamj

#News for #investors and #media: Today we announced the completion of our acquisition of 35Pharma Inc., adding to our Respiratory, Immunology & Inflammation pipeline. Find out more: gsk.to/4ccpQw3

#News for #Investors and #Media: Today at #SGO2026, we’re presenting new data on an investigational antibody-drug conjugate from our oncology pipeline. Learn more: gsk.to/3Q00jh7#News

We're at #SGO26! With an innovative pipeline, we’re building on our strong foundations in oncology research to improve how people live with cancer 🧡 Join us as we share more about our vision for transforming cancer care. 🔗 Learn more: bit.ly/4dz0866

Antibody-drug conjugates (ADCs) - what exactly are they? ➡️ Swipe to find out how this innovation technology works to target cancer cells. 🔗 And dive deeper into the world of ADCs in our latest Behind the Science article: bit.ly/41kHkjL

#News for #Media and #Investors: China's National Medical Products Administration (NMPA) has approved our new therapy for people living with chronic rhinosinusitis with nasal polyps (CRSwNP). For more information, visit: bit.ly/43sHkQ0

The UK-US deal on pharmaceuticals is now finalised, an important step for UK life sciences. Read our short statement ⤵️

#News for #investors and #media: Today we are announcing that our potential treatment for chronic hepatitis B has been accepted for regulatory review in China. Learn more: gsk.to/4uZos7p#News

#News for #Media and #Investors: China’s National Medical Products Administration (NMPA) has approved our new therapy for the treatment of severe asthma. For more information, visit: gsk.to/47tXAlQ

#News for #investors and #media: Today we are announcing that our potential first-in-class treatment for chronic hepatitis B has been accepted for regulatory review by the EMA. Learn more: gsk.to/489nuvm

#News for #Investors and #Media: Today we announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more: gsk.to/4sZtdvP

#News for #investors and #media: Today, we are announcing that one of our liver medicines has been approved by the US Food and Drug Administration (FDA). Find out more: gsk.to/4bHlfke

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded population by the US Food and Drug Administration (FDA). Learn more: gsk.to/4uHdPpM

Published today, our latest Annual Report and Responsible Business Report show our progress in creating value for patients and shareholders. Take a look at the highlights ⤵️ 🔗 Investors and media can read more: gsk.to/4rTabHu

Today we’re at #SLEuro discussing the importance of early intervention and its role in reducing the risk of organ damage progression for patients with lupus and lupus nephritis.

#News for #investors and #media: Today we announced the completion of our acquisition of RAPT Therapeutics, adding to our growing Respiratory, Immunology & Inflammation (RI&I) pipeline. Find out more: gsk.to/4bjpC5H

We’re on the ground at #AAAAI26, sharing our latest #RespiratoryHealth research this week. Stop by Booth 1137 to learn more 🫁

#News for #investors and #media: Today we are announcing our potential treatment for chronic hepatitis B has been accepted for regulatory review in Japan. Learn more: gsk.to/3MKpqTS

News for #Investors and #Media: Today at #CROI2026, our specialist HIV company ViiV Healthcare, presented new insights on our investigational long-acting therapies. 🔗 Find out more on our website: gsk.to/4sfUv0S#Investors

#News for #investors and #media: We’ve announced an agreement to acquire 35Pharma. Find out more: gsk.to/3ZS9thp

News for #Investors and #Media: New data published in the New England Journal of Medicine compare efficacy of different forms of HIV treatment for people with adherence challenges. 🔗 Find out more on our website: gsk.to/40fqNNh#Investors

#News for #Investors and #Media: Today we are presenting new data about one of our vaccines. Learn more: gsk.to/4bZNQ66

#News for #investors and #media: The European Commission has approved our new therapy to treat two respiratory diseases. Learn more here: gsk.to/4tzOptr

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been accepted for review by the China National Medical Products Administration. Learn more: gsk.to/4qnf6Pd

Tuberculosis is a serious and contagious lung disease, with 10 million people worldwide falling ill with it each year. New treatment options are needed, and research collaborations like our work with @dundee.ac.uk are essential to keep innovation at the forefront in the fight against TB.

#News for #investors and #media: We have announced that the European Commission has approved a new therapy for use in adults with chronic obstructive pulmonary disease (COPD). Learn more here: gsk.to/3O0TpXN

Today we announce our strong 2025 performance, driven mainly by Specialty Medicines, and reaffirm our long-term outlooks. Hear more from our CEO Luke Miels ⤵️ More information for media and investors: gsk.to/4r7A5qv $GSK #earnings

Today on #WorldNTDDay, we’re reinforcing our commitment to helping eliminate neglected tropical diseases (NTDs) through our new three-year project with the END Fund. Their expertise means they are ideally placed to deliver this project, helping towards eliminating NTDs 🙌#UniteActEliminate #EndNTDs

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded indication by the European Commission (EC). Learn more: gsk.to/49XpQhi

#News for #investors and #media: We have announced that China’s health authority has approved one of our therapies for use in adults with asthma. Learn more here: gsk.to/4pQb3e1

We’ve announced an agreement to acquire RAPT Therapeutics. Find out more: gsk.to/4qwhWT9

That's a wrap on #JPM2026! We're leaving inspired and confident in our R&D momentum and the future impact of our pipeline. Our approach, built on cutting-edge innovation and industry-leading partnerships, is driving us to get ahead of disease together. Check out our highlights ⤵️ #AheadTogether

Innovation starts when we stop to listen. Patients' experiences fuel our innovation, inspiring us to help people live happier, fuller lives. 🎥 Hear from the people who drive our purpose. #AheadTogether #JPM2026 #JPM26

Heading to #JPM2026? We’re joining our investor and industry partners and sharing how our R&D momentum, pipeline progress and strategic investments are driving innovation for patients. See you there! 🔗 gsk.to/4buPbkT

#News for #Investors and #Media: The European Commission (EC) has approved a new prefilled syringe presentation of one of our vaccines. 👉 Learn more: gsk.to/3LvBgAu

#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programmes for chronic hepatitis B (CHB). This marks an important step towards addressing the global burden of CHB. Learn more: gsk.to/49HDLZM

#News for #investors and #media: A new therapy for two respiratory diseases has received approval from Japan’s health authority. Learn more here: gsk.to/3Lm8ZfI

#News for #investors and #media: We have announced that China’s health authority has approved one of our therapies for use in adults with a respiratory disease. Learn more here: gsk.to/4jqC3PO

Happy New Year from all of us! 🎉 As we step into 2026, our commitments remain strong. We're excited to continue on our journey to get ahead of disease together. What are you looking forward to achieving in 2026?

Season’s greetings from us at GSK to you! 🎄 May your day be filled with peace, happiness and special moments shared with those closest to you ✨